Here Are Some Covid-Related Scientific And Medical Achievements To Be Grateful For This Thanksgiving

Eighteen months into the Covid-19 pandemic, infectious disease expert Dr. Mark Kortepeter explains why he ’s thankful things aren’t worse and is celebrating advances in viral genomics, mRNA vaccines, monoclonal antibodies and other technologies.
Source: Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation Coronavirus Source Type: news

Related Links:

The U.S. Army is working on a pan-coronavirus vaccine that will be effective against all future strains of the virus, and could even prevent future pandemics from occuring.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
With spotty immunity in the population and a churn of new variants, the coronavirus is likely to become a persistent but hopefully manageable threat.
Source: NYT Health - Category: Consumer Health News Authors: Tags: your-feed-science Coronavirus Omicron Variant Coronavirus (2019-nCoV) Vaccination and Immunization Disease Rates Epidemics Source Type: news
Thank you for your leadership in serving as Editor-in-Chief for The Journal for Nurse Practitioners, a premier national and international journal dedicated to nursing profession, health care profession, and patient care. I applaud your leadership in your column on “COVID-19 Vaccine—Your Ethical Responsibility” (J Nurse Pract. 2021;17[10]:1157-1158) and THANK YOU! This is an unprecedented time during which the coronavirus disease 2019 pandemic infiltrates all lives globally and a call for health care practitioners including nurses, physicians, pharmacist s, and all other health care providers to step up, d...
Source: The Journal for Nurse Practitioners - Category: Nursing Authors: Tags: Letter to the Editor Source Type: research
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has lasted more than 2 years with over 260 million infections and 5 million deaths worldwide as of November 2021. To combat the virus, monoclonal antibodies blocking the virus binding to human receptor, the angiotensin converting enzyme 2 (ACE2), have been approved to treat the infected patients. Inactivated whole virus or the full-length virus spike encoding adenovirus or mRNA vaccines are being used to immunize the public. However, SARS-CoV-2 variants are emerging. These, to some extent, escape neutralization by the therapeutic antibodies and ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
n Pi-Sheng Wang The Severe Acute Respiratory Syndrome-associated Coronavirus 2 (SARS-CoV-2) was an outbreak in December, 2019 and rapidly spread to the world. All variants of SARS-CoV-2, including the globally and currently dominant Delta variant (Delta-SARS-CoV-2), caused severe disease and mortality. Among all variants, Delta-SARS-CoV-2 had the highest transmissibility, growth rate, and secondary attack rate than other variants except for the new variant of Omicron that still exists with many unknown effects. In Taiwan, the pandemic Delta-SARS-CoV-2 began in Pingtung from 14 June, 2021 and ceased at 11 July, 2021. ...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
ConclusionsOverall, our studies substantiate and expand the growing body of literature focused on understanding key human coronavirus-host cell interactions and exploit that knowledge for rational antiviral drug development.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
Kim Hong-Gi Kim Coronavirus disease 2019 (COVID-19), the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is characterized by symptoms such as fever, fatigue, a sore throat, diarrhea, and coughing. Although various new vaccines against COVID-19 have been developed, early diagnostics, isolation, and prevention remain important due to virus mutations resulting in rapid and high disease transmission. Amino acid substitutions in the major diagnostic target antigens of SARS-CoV-2 may lower the sensitivity for the detection of SARS-CoV-2. For this reason, we developed specific monoclonal ant...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
When Jeremy Luban first looked over the genetic sequence of the Omicron variant on his phone one day last November, it was five o’clock in the morning. But even at that hour, the University of Massachusetts virus expert knew right away Omicron was a problem. First, there was the sheer number of new mutations—by some counts, as many as 50, with 30 of them in the critical places that vaccines and drug treatments target. Second, this new version of the SARS-CoV-2 virus seemed to appear out of nowhere, unpredictably and with no immediately obvious connection to previous variants. [time-brightcove not-tgx=”tru...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Pfizer and BioNTech announced they have begun a clinical trial for an Omicron-specific Covid-19 vaccine. Follow here for the latest news updates. #biontech #omicron #pfizer
Source: Reuters: Health - Category: Consumer Health News Source Type: news
Pfizer Inc Chief Executive Albert Bourla said on Saturday that an annual COVID-19 vaccine would be preferable to more frequent booster shots in fighting the coronavirus pandemic.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
More News: Coronavirus | COVID-19 | Infectious Diseases | Pandemics | Pharmaceuticals | Vaccines